ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0706

The Impact of COVID on CRRT Filter Lifespan

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Mann, Lewis, University of Iowa, Iowa City, Iowa, United States
  • Fraer, Mony, University of Iowa, Iowa City, Iowa, United States
  • Kuppachi, Sarat C., University of Iowa, Iowa City, Iowa, United States
  • Noureddine, Lama A., University of Iowa, Iowa City, Iowa, United States
  • Antes, Lisa M., University of Iowa, Iowa City, Iowa, United States
  • Jenigiri, Sreedevi koppisetti, University of Iowa, Iowa City, Iowa, United States
  • Story, Maria T., University of Iowa, Iowa City, Iowa, United States
  • Sambharia, Meenakshi, University of Iowa, Iowa City, Iowa, United States
  • Patel, Jayesh B., University of Iowa, Iowa City, Iowa, United States
  • O'Connor, Kandi, University of Iowa, Iowa City, Iowa, United States
  • Griffin, Benjamin R., University of Iowa, Iowa City, Iowa, United States
Background

Patients with COVID are more likely to have systemic thrombotic events. Although it has been theorized that those on CRRT also have an increased rate of filter loss due to clotting. If COVID-positive patients are more likely to clot their filter than other patients on CRRT, a more aggressive anticoagulation strategy may be worthwhile. This could result in longer filter lifespan, less circuit down time, which would result in improved clearance, lower costs, less risk of iatrogenic blood loss, and less wasted nursing time. If there is no difference in filter lifespan between COVID positive and negative patients, then more aggressive anticoagulation would result only in added risk without a clear benefit.

Methods

We analyzed COVID data on patients in a related unblinded prospective randomized trial, in which patients are assigned to either pre-filter CVVH or CVVHD. The standard treatment protocol at the University of Iowa is to use citrate anticoagulation with a blood flow rate of 200 mL/min and a dose of 25 mL/kg/hr.

The primary outcome is average filter life, and secondary outcomes are mortality, intensive care unit LOS, hospital LOS, and renal recovery.

Results

A total 30 patients using a total of 90 filters from March 25 to May 20, 2020 were evaluated (Table 1). The average filter life in COVID-positive patients was 37.4 +/- 35.8 compared to 33.1 +/- 26.7 in COVID-negative patients (p = 0.55). However, COVID-19 patients were more likely to receive heparin anticoagulation in addition to citrate.

Conclusion

Contrary to other reports, in this retrospective, unadjusted analysis of CRRT patients, the presence of COVID-19 did not decrease average filter life. Further research is needed regarding the appropriate anticoagulation strategy in COVID-19 positive patients.

Table 1: Patient characteristics
 COVID-positive (n = 8)COVID-negative (n = 16)p value
Age53.6 +/- 13.959.2 +/- 16.00.41
Male (%)8 (100%)7 (44%)0.0089
Caucasian (%)1 (13%)14 (88%)< 0.01
Hispanic (%)7 (88%)0 (0%)< 0.01
Black (%)0 (0%)1 (6.3%)< 0.01
SOFA9.25 +/- 1.9810.4 +/- 2.850.32
CVVH (%)5 (63%)8 (53%)0.65
Diabetes (%)4 (50%)11 (69%)0.37
CAD / HF (%)0 (0%)5 (31%)0.084